Insulin is a 51-amino-acid peptide hormone synthesized and secreted by the beta cells of the islets of Langerhans in the endocrine pancreas, and it serves as the primary anabolic, glucose-lowering hormone in the body. It is distinguished from glucagon (the counter-regulatory alpha-cell hormone that raises blood glucose), proinsulin (its inactive precursor), and C-peptide (the cleavage byproduct used clinically to distinguish endogenous from exogenous insulin production). The core physiological mechanism involves insulin binding to its tyrosine kinase receptor on target cell membranes (primarily hepatocytes, skeletal muscle, and adipocytes), triggering GLUT4 transporter translocation to the cell surface, facilitating glucose uptake, and simultaneously suppressing hepatic glycogenolysis and gluconeogenesis. Insulin may be physiological (endogenous secretion in a non-diabetic) or pharmacological (exogenously administered as therapy in Type 1 DM E10.9, Type 2 DM E11.9, or other DM types), with long-term use captured by the Z-code Z79.4. Clinically relevant subtypes from a coding perspective include insulin used as a therapeutic agent (Z79.4), insulin as the cause of an adverse effect (T38.3X5A), insulin in the context of poisoning (T38.3X1A, T38.3X2A), and endogenous hyperinsulinism (E16.1, E16.0). Insulin is commonly confused with insulinoma (a tumor that secretes autonomous insulin) and insulin resistance (a state where target tissues fail to respond normally to insulin), both of which are distinct clinical and coding entities.
Noun-forming suffix for chemical substances, especially proteins, hormones, and biochemical compounds — “substance derived from” or “substance of”
The word entered English in 1922 as insulin (noun), coined by Sir Edward Sharpey-Schafer in 1916 (from the Latin insula, “island”) and later adopted by Banting and Best upon their isolation of the active pancreatic extract — literally “substance of the islands.” The root insula (“island”) connects insulin to the broader insul- root family: insulinoma (insul- + -oma → “tumor of the islet cells”), insulinogenic (insul- + -genic → “producing insulin”), and insulitis (insul- + -itis → “inflammation of the islets,” as in autoimmuneT1DM). The suffix -in is among the most productive in endocrine pharmacology, also appearing in heparin, oxytocin, vasopressin, thyrotropin, and prolactin.
Exogenous insulin(pharmacologically administered insulin; source of adverse effects and overdose events; triggers T38.3X5A for adverse effects when taken as prescribed)
Endogenous insulin(insulin produced naturally by the patient’s own beta cells; diminished or absent in Type 1 DM; measured indirectly via C-peptide assay)
Insulin therapy(clinical descriptor for long-term therapeutic insulin use; requires Z79.4 as an additional code on all encounters for Type 2 DM patients on insulin)
Insulinogenic(adjective — capable of stimulating insulin secretion; used in pharmacology to describe insulinogenic index of foods or drugs — e.g., GLP-1 agonists)
Proinsulin(inactive single-chain precursor to insulin cleaved in beta-cell secretory granules; elevated in insulinoma — measured via serum proinsulin assay)
C-peptide(cleavage fragment released equimolarly with endogenous insulin; used to differentiate endogenous from exogenous insulin production; key in factitious hypoglycemia workup)
Insulin resistance(state of diminished cellular responsiveness to insulin; key pathophysiological driver of Type 2 DM and metabolic syndrome; coded as part of DM combination codes)
Insulinoma(pancreatic islet beta-cell tumor causing autonomous insulin hypersecretion and fasting hypoglycemia; benign form D13.7, malignant C25.4)
Hyperinsulinemia(elevated serum insulin level; may be endogenous [insulinoma, PCOS, metabolic syndrome] or exogenous [overdose]; coded via E16.1 or T38.3x poisoning codes depending on etiology)
Basal insulin(long-acting insulin formulation providing background glucose control between meals and overnight; e.g., insulin glargine, detemir — coded under Z79.4 + appropriate DM code)
Bolus insulin(rapid-acting insulin administered with meals to cover postprandial glucose excursions; e.g., insulin lispro, aspart — coded under Z79.4 + appropriate DM code)
🔗 RELATED TERMS
Glucagon — the direct counter-regulatory hormone to insulin; secreted by pancreatic alpha cells in response to hypoglycemia to raise blood glucose via glycogenolysis; therapeutic glucagon injection coded via CPT 96372
Proinsulin — shares the insul- root; the inactive single-chain precursor to insulin; elevated in insulinoma and provides diagnostic specificity when insulin levels are elevated
C-peptide — the connecting peptide cleaved during proinsulin-to-insulin conversion; absent when exogenous insulin is the sole source; key in factitious hypoglycemia and legal/forensic cases
Insulinoma — shares the insul- root; pancreatic islet beta-cell neoplasm that secretes insulin autonomously; benign D13.7, malignant C25.4
Insulin resistance — pathological state in which GLUT4 translocation fails to occur adequately despite normal or elevated insulin; core mechanism of Type 2 DM and metabolic syndrome
hypoglycemia — the primary adverse consequence of excess insulin action, whether from therapeutic overdose, insulinoma, or counter-regulatory failure; coded E16.0 (drug-induced), E11.649 (T2DM), etc.
Hyperglycemia — the consequence of insulin deficiency or resistance; coded R73.09 (non-diabetic NOS) or E11.65 (T2DM with hyperglycemia)
Diabetic ketoacidosis (DKA) — life-threatening complication of absolute insulin deficiency (primarily T1DM); coded E10.10 (Type 1 DM with ketoacidosis without coma) or E10.11 (with coma)
GLP-1 receptor agonist — incretin-based pharmacotherapy that augments insulin secretion and suppresses glucagon in a glucose-dependent manner; an insulin-sparing agent in T2DM management
GLUT4 — insulin-sensitive glucose transporter responsible for facilitated diffusion of glucose into muscle and fat cells; its translocation is the key molecular mechanism of insulin action
Islets of Langerhans — the pancreatic endocrine microstructures (insulae) that house beta cells (insulin), alpha cells (glucagon), delta cells (somatostatin), and PP cells; the anatomical namesake of insulin
Hemoglobin A1c — the 2-3 month glycemic average that reflects cumulative glucose exposure; its reduction is the primary therapeutic goal of insulin therapy; CPT 83036
CODING CORNER
🏥 ICD-10-CM CODES
Long-Term Insulin Use | Z-Code (Always Code as Additional)
Critical care, first 30-74 minutes (severe insulin overdose / hypoglycemic coma — inpatient critical care)
⚠️ Coding Note: The most critical inpatient profee insulin coding rule is the Z79.4 requirement — per ICD-10-CM Official Guidelines, Z79.4 must be assigned as an additional code whenever a Type 2 DM patient is documented as using insulin, even if it is already implied by the clinical picture. This code is not required for Type 1 DM since insulin dependence is inherent to the diagnosis. The most common inpatient profee missed code is T38.3X5A on encounters where insulin caused a hypoglycemic event — if the patient took their insulin as prescribed and developed hypoglycemia, that is an adverse effect, not a poisoning; the adverse effect code must be sequenced after the manifestation code (e.g., E11.649 first, then T38.3X5A). Conversely, if the patient took too much insulin — whether accidentally or intentionally — the correct code is a poisoning code from T38.3X1-T38.3X4, and the hypoglycemia is then coded as a manifestation of the poisoning, not as a diabetic combination code. On inpatient charts, the documentation trigger phrases to watch for are “insulin-induced hypoglycemia,” “accidental insulin overdose,” “self-administered excess insulin,” and “insulin shock” — each points to a distinct coding pathway that, if undercoded, may result in a compliance vulnerability or MS-DRG impact.
Crystal's Coder Hub